AngioDynamics, Inc.
ANGONASDAQHealthcare● Active
$11.93
$-0.01(-0.08%)
Market Cap$492934477
P/E Ratio—
52W High$13.99
52W Low$8.36
AngioDynamics, Inc. (ANGO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANGO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 2, 2026EPS Actual
-$0.07
Est. -$0.11 · +36.4%
Revenue
$0.08B
Est. $0.08B · +2.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 2, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
ANGO reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 21, 2026 | -$0.11 | — | — | — | $0.08B | — |
| ▲ Q2 FY2026 | Apr 2, 2026 | -$0.11 | -$0.07 | +36.4% | $0.08B | $0.08B | +2.2% |
| ▼ Q1 FY2026 | Jan 6, 2026 | -$0.10 | -$0.15 | -50.0% | $0.08B | $0.08B | +3.9% |
| ▲ Q4 FY2025 | Oct 2, 2025 | -$0.14 | -$0.10 | +28.6% | $0.08B | $0.08B | -0.8% |
| ▲ Q3 FY2025 | Jul 15, 2025 | -$0.13 | -$0.03 | +76.9% | $0.08B | $0.07B | +8.0% |
| ▲ Q2 FY2025 | Apr 2, 2025 | -$0.13 | $0.03 | +123.1% | $0.07B | $0.07B | -3.0% |
| ▲ Q1 FY2025 | Jan 8, 2025 | -$0.11 | -$0.04 | +63.6% | $0.07B | $0.07B | +3.2% |
| ▲ Q4 FY2024 | Oct 3, 2024 | -$0.15 | -$0.11 | +26.7% | $0.07B | $0.07B | -0.7% |
Q3 FY2026
Jul 21, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 2, 2026Beat
EPS Actual
-$0.07
EPS Est.
-$0.11
EPS Surpr.
+36.4%
Revenue
$0.08B
Q1 FY2026
Jan 6, 2026Miss
EPS Actual
-$0.15
EPS Est.
-$0.10
EPS Surpr.
-50.0%
Revenue
$0.08B
Q4 FY2025
Oct 2, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.14
EPS Surpr.
+28.6%
Revenue
$0.08B
Q3 FY2025
Jul 15, 2025Beat
EPS Actual
-$0.03
EPS Est.
-$0.13
EPS Surpr.
+76.9%
Revenue
$0.08B
Q2 FY2025
Apr 2, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.13
EPS Surpr.
+123.1%
Revenue
$0.07B
Q1 FY2025
Jan 8, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.11
EPS Surpr.
+63.6%
Revenue
$0.07B
Q4 FY2024
Oct 3, 2024Beat
EPS Actual
-$0.11
EPS Est.
-$0.15
EPS Surpr.
+26.7%
Revenue
$0.07B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.01 | $0.01 | $0.01 | 1 |
| Q1 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q4 FY2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2026 | $-0.11 | $-0.10 | $-0.08 | 2 |
| Q2 FY2026 | $-0.12 | $-0.09 | $-0.06 | 2 |
| Q1 FY2026 | $-0.11 | $-0.10 | $-0.10 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 2, 2026 | +36.4% | $11.94 | $10.31 | -13.65% |
| ▼ Q1 FY2026 | Jan 6, 2026 | -50.0% | $13.23 | $11.44 | -13.53% |
| ▲ Q4 FY2025 | Oct 2, 2025 | +28.6% | $11.07 | $11.74 | +6.05% |
| ▲ Q3 FY2025 | Jul 15, 2025 | +76.9% | $9.63 | $8.65 | -10.18% |
| ▲ Q2 FY2025 | Apr 2, 2025 | +123.1% | $9.66 | $10.86 | +12.42% |
| ▲ Q1 FY2025 | Jan 8, 2025 | +63.6% | $9.40 | $12.94 | +37.66% |
| ▲ Q4 FY2024 | Oct 3, 2024 | +26.7% | $7.65 | $6.37 | -16.73% |
| ▲ Q3 FY2024 | Jul 16, 2024 | +70.0% | $5.93 | $7.51 | +26.64% |
Q2 FY2026-13.65%
Report Date
Apr 2, 2026
EPS Beat/Miss
+36.4%
Price Before
$11.94
Price After
$10.31
Q1 FY2026-13.53%
Report Date
Jan 6, 2026
EPS Beat/Miss
-50.0%
Price Before
$13.23
Price After
$11.44
Q4 FY2025+6.05%
Report Date
Oct 2, 2025
EPS Beat/Miss
+28.6%
Price Before
$11.07
Price After
$11.74
Q3 FY2025-10.18%
Report Date
Jul 15, 2025
EPS Beat/Miss
+76.9%
Price Before
$9.63
Price After
$8.65
Q2 FY2025+12.42%
Report Date
Apr 2, 2025
EPS Beat/Miss
+123.1%
Price Before
$9.66
Price After
$10.86
Q1 FY2025+37.66%
Report Date
Jan 8, 2025
EPS Beat/Miss
+63.6%
Price Before
$9.40
Price After
$12.94
Q4 FY2024-16.73%
Report Date
Oct 3, 2024
EPS Beat/Miss
+26.7%
Price Before
$7.65
Price After
$6.37
Q3 FY2024+26.64%
Report Date
Jul 16, 2024
EPS Beat/Miss
+70.0%
Price Before
$5.93
Price After
$7.51
Avg Beat Reaction+6.03%
Avg Miss Reaction-13.53%
Beat Rate7 / 8 quarters
Largest Move+37.66% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANGO ends December
AngioDynamics, Inc. (ANGO) most recently reported earnings on April 2, 2026 for Q2 FY2026, posting EPS of $-0.07 — beating the analyst consensus of $-0.11 by +36.4%. The next ANGO earnings date is expected around September 1, 2026.
Each quarter, investors track ANGO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANGO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANGO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANGO earnings · 5 questionsAngioDynamics, Inc.'s next earnings report is expected around September 1, 2026. ANGO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANGO historically reports after market close (AMC).
ANGO earnings datewhen is ANGO earningsANGO next earnings datewhen does ANGO report earningsANGO earnings calendar
▸ Source: FMP · AngioDynamics, Inc. SEC filings · US GAAP · AngioDynamics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026